Iseri K, et al. - Researchers conducted a prospective, three-center study to determine if denosumab and alendronate are effective and safe treatments in patients with hemodialysis. Participants in the study were 48 hemodialysis patients who were diagnosed as having osteoporosis and had not received anti-osteoporotic agents previously. For this investigation, participants were randomized to either denosumab or intravenous alendronate and in the first 2 weeks, all subjects received elemental calcium and calcitriol. In hemodialysis patients with osteoporosis, denosumab and alendronate treatment improved lumbar spine bone mineral density, reduced bone turnover markers and seemed to be safe.